The Contrarian View: Let's Not Put All Our Money On Lorcaserin Just Yet

Healthcare Sector and Stocks Analysis from Seeking Alpha

Fri, 7 Dec 2012

By Ed Liston : On the face of it, the FDA's approval of Arena Pharmaceuticals' ( ARNA ) Lorcaserin as an effective obesity drug is a buy signal. More so because this is the first obesity drug that the FDA has approved in 13 years, excluding Qsymia from Vivus ( VVUS ). Apparently there are plenty of ...

Read the rest of this article on Healthcare Sector and Stocks Analysis from Seeking Alpha

Related Topics:

Content Partners

Site Directory Site Map Our Products

Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News

International Sites: Australia Canada China France Germany Hong Kong Italy The Netherlands Norway Spain U.K. Switzerland India Finland

Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.